No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
VCYT240621P22500
- 2.71
- 0.000.00%
15min DelayClose Jun 14 15:59 ET
0.00High0.00Low
2.71Open2.71Pre Close0 Volume23 Open Interest22.50Strike Price0.00Turnover160.68%IV5.63%PremiumJun 21, 2024Expiry Date1.53Intrinsic Value100Multiplier6DDays to Expiry1.18Extrinsic Value100Contract SizeAmericanOptions Type-0.5857Delta0.0866Gamma7.74Leverage Ratio-0.1375Theta-0.0025Rho-4.53Eff Leverage0.0109Vega
Intraday
- 5D
- 1D
News
Veracyte(VCYT.US) Director Sells US$79,683.3 in Common Stock
$Veracyte(VCYT.US)$ Director EASTHAM KARIN sold 3,870 shares of common stock on Jun 11, 2024 at an average price of $20.59 for a total value of $79,683.3.Source: Announcement What is statement of chan
Veracyte(VCYT.US) Director Sells US$78,633.76 in Common Stock
$Veracyte(VCYT.US)$ Director Bhanji Muna sold 3,870 shares of common stock on Jun 10, 2024 at an average price of $20.3188 for a total value of $78,633.76.Source: Announcement What is statement of cha
Veracyte(VCYT.US) Director Sells US$52,425 in Common Stock
$Veracyte(VCYT.US)$ Director EASTHAM KARIN sold 2,500 shares of common stock on Jun 7, 2024 at an average price of $20.97 for a total value of $52,425.Source: Announcement What is statement of changes
Veracyte (VCYT) Up 8.4% Since Last Earnings Report: Can It Continue?
It's Unlikely That The CEO Of Veracyte, Inc. (NASDAQ:VCYT) Will See A Huge Pay Rise This Year
Veracyte (NASDAQ:VCYT) Investors Are Sitting on a Loss of 40% If They Invested Three Years Ago
Comments
Analysts are slightly more optimistic about Veracyte's losses per share, but expect its revenue growth to slow down substantially compared to its historical 29% growth rate. The wider industry is expected to outpace Veracyte.
Veracyte, Inc. (NASDAQ:VCYT) Just Released Its Annual Results And Analysts Are Updating Their Estimates 1
The absence of any insider transactions in the past three months doesn't reveal much. Low insider ownership and previous insider selling at Veracyte sparks less enthusiasm. Investors should be aware of potential risks associated with the company.
Gapping up
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US$ +11.3%, $Cardiff Oncology(CRDF.US$ +9%, $Immatics(IMTX.US$ +8.3%, $IDEAYA Biosciences(IDYA.US$ +8%, $Lyra Therapeutics(LYRA.US$ +5.7%, $POINT Biopharma(PNT.US$ +5.7%, $Edgewise Therapeutics(EWTX.US$ +4.7%, $Concert Pharmaceuticals(CNCE.US$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US$ +3.2%, $Veracyte(VCYT.US$ +2.6%, $SpringWorks Therapeutics(SWTX.US$ +2.3%, ...
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US$ +11.3%, $Cardiff Oncology(CRDF.US$ +9%, $Immatics(IMTX.US$ +8.3%, $IDEAYA Biosciences(IDYA.US$ +8%, $Lyra Therapeutics(LYRA.US$ +5.7%, $POINT Biopharma(PNT.US$ +5.7%, $Edgewise Therapeutics(EWTX.US$ +4.7%, $Concert Pharmaceuticals(CNCE.US$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US$ +3.2%, $Veracyte(VCYT.US$ +2.6%, $SpringWorks Therapeutics(SWTX.US$ +2.3%, ...
10
Gainers:
• $Theravance Biopharma(TBPH.US$ +15.9% (TBPH to sell all of its units in Theravance Respiratory to RPRX for over $1.5 bln)
• $Amryt Pharma(AMYT.US$ +11.9% (FDA grants Orphan Drug Designation to Mycapssa for the treatment of Carcinoid Syndrome)
• $Green Brick Partners(GRBK.US$ +7.3% (to join S&P SmallCap 600)
• $TransGlobe Energy(TGA.US$ +6.9% (Transglobe Energy to be acquired by VALLCO Energy (EGY) in stock-for-stock...
• $Theravance Biopharma(TBPH.US$ +15.9% (TBPH to sell all of its units in Theravance Respiratory to RPRX for over $1.5 bln)
• $Amryt Pharma(AMYT.US$ +11.9% (FDA grants Orphan Drug Designation to Mycapssa for the treatment of Carcinoid Syndrome)
• $Green Brick Partners(GRBK.US$ +7.3% (to join S&P SmallCap 600)
• $TransGlobe Energy(TGA.US$ +6.9% (Transglobe Energy to be acquired by VALLCO Energy (EGY) in stock-for-stock...
10
1
Read more